2,4,7-Trimethyl-8H-pyrido[2,3-d]pyrimidin-5-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 2,4,7-Trimethyl-8H-pyrido[2,3-d]pyrimidin-5-one
• 英文别名: Pyrido[2,3-d]pyrimidin-5(8H)-one, 2,4,7-trimethyl-
• 化学式: C₁₀H₁₁N₃O
• mdl: MFCD01451114
• 分子量: 189.217
• InChiKey: BZMOFCOWQNFMNE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N'-(5-Acetyl-2,6-dimethyl-pyrimidin-4-yl)-N,N-dimethyl-acetamidine 在 sodium methylate 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 2,4,7-Trimethyl-8H-pyrido[2,3-d]pyrimidin-5-one
  参考文献：
  名称：

  Efficient methods for the synthesis of pyrido[2,3-d]pyrimidin-5-ones from 4-amino-5-acetylpyrimidines

  摘要：

  New methods for annelation of a pyridine ring to a pyrimidine ring were suggested. Substituted 8H-pyrido[2,3-d]pyrimidin-5-ones (8a-f) were synthesized by the interaction of 2,6-disubstituted 4-amino-5-acetylpyrimidines (1-4) with formamide or acetamide acetals followed by cyclization under the action of sodium methoxide in methanol. 2,4-Disubstituted 7-phenyl-8H-pyrido[2,3-d]pyrimidin-5-ones (11a-c) were prepared by the reaction of 2,6-disubstituted 5-acetyl-4-benzoylaminopyrimidines (10a-c) with MeONa in boiling BuOH.

  DOI：

  10.1007/bf00703702

文献信息

• IDO Inhibitors
  申请人：Mautino Mario

  公开号：US20110053941A1

  公开（公告）日：2011-03-03

  Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

  目前提供以下方法：(a) 通过接触本文中描述的化合物的调节有效量与吲哚胺2,3-二氧化酶相互作用，从而调节吲哚胺2,3-二氧化酶的活性；(b) 治疗需要吲哚胺2,3-二氧化酶(IDO)介导的免疫抑制的患者，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(c) 治疗需要抑制吲哚胺-2,3-二氧化酶酶活性的医疗状况，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(d) 增强抗癌治疗的有效性，包括给予抗癌剂和本文中描述的化合物；(e) 治疗与癌症相关的肿瘤特异性免疫抑制，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量；(f) 治疗与传染病相关的免疫抑制，例如HIV-1感染，包括给予本文中描述的化合物的有效吲哚胺2,3-二氧化酶抑制剂量。